Navigation Links
Telik Announces Financial Results for 2008 Third Quarter
Date:11/5/2008

Research and development expenses for the quarter ended September 30, 2008 were $4.8 million, compared to $8.2 million in the second quarter of 2008 and $9.4 million for the third quarter in 2007. General and administrative expenses for the quarter ended September 30, 2008 were $2.8 million, compared to $2.8 million in the prior quarter and $3.7 million for the comparable period in 2007.

For the nine months ended September 30, 2008, Telik reported a net loss of $31.4 million, or $0.59 per share, compared with a net loss of $42.3 million, or $0.81 per share, for the nine months ended September 30, 2007. Total operating expenses for the first nine months of 2008 were $29.5 million, compared with $46.8 million for the first nine months of 2007. Operating expenses in the first nine months of 2008 included approximately $4.9 million in stock-based compensation expense. The reduction in operating expenses of approximately 37% in the first nine months of 2008 compared with the same period in 2007 was primarily due to reduced clinical trial and related expenses, lower headcount and administrative expenses as well as lower stock-based compensation expense.

Conference Call and Webcast

Telik will conduct its quarterly conference call today at 4:30 p.m. Eastern time (1:30 pm. Pacific time). The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-398-9367 or 612-332-7517. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 966597. The archive will be available from approximately 6:30 p.m. Eastern time on November 5 through November 19, 2008.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational dr
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
2. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
3. Telik Announces Receipt of Nasdaq Notice
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. ReceptorBio Announces Diabetes License Agreement With Telik
6. Telik Announces Financial Results For 2008 Second Quarter
7. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces First Quarter 2008 Financial Results
11. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ... negative is the housing market remaining soft. , This solid ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... Azur Pharma Limited ("Azur,Pharma") today announced that ... Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R),(carbidopa-levodopa orally ... Fluxid(TM) (famotidine orally,disintegrating tablets) from UCB (Euronext: ... Niravam, Parcopa and Kemstro ...
... The readers of The IN VIVO Blog , which ... device industries, have selected a Deal of the Year ... with Takeda Pharmaceuticals .More than 2,500 reader votes were cast ... start to finish among the 13 nominees selected by The ...
... (Nasdaq: MATK ) announced today that it will ... conference. The conference is being held January 14-15, 2009 ... Dana Point, California. Peter L. Buzy, Chief Financial Officer, ... 14, 2009 at 1:25 PM PT.A live audio webcast of ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of Medicine have just developed an advanced imaging technique ... or white blood cells. Microdomains are restricted areas on ... signaling molecules accumulate during cell activation. Using digital multi-channel ... subsets and their forming microdomains in the vascular system ...
... single-walled carbon nanotubes (SWCNTs) shorter than about 200 nanometers ... pose an increased risk to health, according to scientists ... The results of their laboratory studies appear in an ... uses ranging from electronic displays to fuel cells to ...
... of Michigan analytical chemist Kristina Hakansson sets the stage ... growing body of evidence points to assemblies of sugars ... as accomplices in the growth and spread of tumors. ... traditional analytical methods have not been sufficient. , ...
Cached Biology News:New imaging technique tracks traffic patterns of white blood cells 2Cells selectively absorb short nanotubes 2A sweet step toward new cancer therapies 2
Rab1A...
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: